Pharming Group (NASDAQ:PHAR) Trading Down 8.8%

Pharming Group (NASDAQ:PHAR)’s share price fell 8.8% on Friday . The stock traded as low as $9.53 and last traded at $9.53. 1,241 shares were traded during trading, a decline of 52% from the average session volume of 2,603 shares. The stock had previously closed at $10.45.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research note on Thursday, March 14th.

Pharming Group Stock Down 6.2 %

The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.33 and a current ratio of 4.06. The stock has a market capitalization of $657.68 million, a price-to-earnings ratio of -68.07 and a beta of 0.16. The firm’s fifty day simple moving average is $10.86 and its 200 day simple moving average is $11.43.

Pharming Group (NASDAQ:PHAR) last released its earnings results on Thursday, March 14th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.08). Pharming Group had a negative net margin of 4.13% and a negative return on equity of 4.53%. The firm had revenue of $81.20 million during the quarter, compared to the consensus estimate of $71.83 million. On average, sell-side analysts forecast that Pharming Group will post -0.02 earnings per share for the current year.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. Silverberg Bernstein Capital Management LLC acquired a new position in shares of Pharming Group (NASDAQ:PHAR) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 17,710 shares of the company’s stock, valued at approximately $202,000. 0.03% of the stock is owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks.